Related Experiment Video
Updated: Feb 2, 2026

Reconstitution of Actin-Based Motility with Commercially Available Proteins
Published on: October 28, 2022
Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis
Sarah Nersesian1,2, Rodette Williams1,2, Daniel Newsted1,2
1Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Abstract:
Amplification of HER2 leads to development of HER2-positive (HER2+) cancers with high rates of metastasis compared to other cancer subtypes. The goal of this study was to probe the vulnerability of HER2+ cancer cells to a filamentous actin (F-actin) severing and capping toxin. The growth and viability of human HER2+ breast cancer (HCC1954) and ovarian cancer (SKOV3) cell lines were significantly impaired upon treatment with the marine macrolide mycalolide B (Myc B) at doses above 100 nanomolar. Further testing of Myc B in combination with the antibody-drug conjugate Trastuzumab-emtansine (T-DM1) led to improved killing of SKOV3 cells compared to either treatment alone. At sub-lethal doses, treatment of HER2+ cancer cells with Myc B resulted in rapid loss of leading edge protrusions and formation of aggresomes containing F-actin and the actin regulatory protein Cortactin. This correlated with robust inhibition of HER2+ cancer cell motility and invasion with Myc B treatment. In SKOV3 tumor xenograft assays, intratumoral injections of Myc B impaired HER2+ tumor growth and metastasis, with maximal effects observed in combination with systemic delivery of Trastuzumab. Metastasis of SKOV3 cells to the lungs following tail vein injection was also reduced by Myc B. Together, these findings provide rationale for targeting F-actin in combination with existing therapies for HER2+ cancers to reduce metastasis.
Insights
Marine toxin mycalolide B impairs HER2-positive cancer growth and metastasis by targeting filamentous actin. Combining mycalolide B with therapies like Trastuzumab shows promise for reducing cancer spread.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- HER2-amplified cancers exhibit high metastatic potential.
- Targeting cellular structures like the actin cytoskeleton presents a novel therapeutic strategy.
Purpose of the Study:
- To investigate the efficacy of mycalolide B, a filamentous actin (F-actin) severing toxin, against HER2-positive (HER2+) cancer cells.
- To evaluate mycalolide B in combination with Trastuzumab-emtansine (T-DM1) for enhanced anti-cancer effects.
Main Methods:
- Treatment of HER2+ breast (HCC1954) and ovarian (SKOV3) cancer cell lines with mycalolide B.
- Assessment of cell viability, motility, and invasion.
- In vivo studies using SKOV3 tumor xenografts and tail vein injection models.
- Combination therapy studies with mycalolide B and Trastuzumab or T-DM1.
Main Results:
- Mycalolide B significantly impaired growth and viability of HER2+ cancer cells at nanomolar doses.
- Sub-lethal mycalolide B doses inhibited cancer cell motility, invasion, and caused loss of leading edge protrusions.
- Combination therapy with mycalolide B and Trastuzumab demonstrated maximal impairment of tumor growth and metastasis in vivo.
- Mycalolide B reduced lung metastasis in a tail vein injection model.
Conclusions:
- Mycalolide B effectively targets F-actin in HER2+ cancer cells, reducing their growth, motility, and metastatic potential.
- Combination of mycalolide B with existing HER2-targeted therapies like Trastuzumab offers a promising strategy to combat metastasis in HER2+ cancers.
Related Concept Videos
Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate....
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Microtubules in Cell Motility
The Role of Actin and Myosin in Non-muscle Cells
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Actin Treadmilling

